<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03639155</url>
  </required_header>
  <id_info>
    <org_study_id>AKB-6548-CI-0027</org_study_id>
    <nct_id>NCT03639155</nct_id>
  </id_info>
  <brief_title>A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults</brief_title>
  <official_title>A Randomized, Open-Label, Single-Dose, Two-Period Crossover Study in Healthy Adults to Assess Bioequivalence Between Test and Reference Formulations of Vadadustat 150 mg Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akebia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akebia Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the bioequivalence of a test formulation of vadadustat (A) compared
      to a reference formulation of vadadustat (B)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, single-dose, two-period crossover study in healthy adults
      to assess the bioequivalence of a test formulation of vadadustat compared to the reference
      formulation of vadadustat. Blood samples for vadadustat PK will be collected at pre-dose (0
      hour) and at 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 18, 24, 32, 40, and 48 hours post-dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 12, 2018</start_date>
  <completion_date type="Actual">May 23, 2018</completion_date>
  <primary_completion_date type="Actual">May 23, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration-time curve from 0 to infinity (AUCinf)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under plasma concentration-time curve from 0 to last sampling point (AUCall)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Observed maximum concentration (Cmax)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Tmax</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time (MRT)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (Kel)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CL/F)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vd/F)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2)</measure>
    <time_frame>Baseline visit, 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Regimen A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vadadustat reference tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vadadustat test tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadadustat reference tablets</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Regimen A</arm_group_label>
    <other_name>AKB-6548</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadadustat test tablets</intervention_name>
    <description>oral tablet</description>
    <arm_group_label>Regimen B</arm_group_label>
    <other_name>AKB-6548</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 55 years of age, inclusive, at time of informed consent.

          -  Healthy subjects per Investigator judgment as documented by the medical history,
             physical examination, vital sign assessments, 12-lead electrocardiogram (ECG),
             clinical laboratory assessments, and general observations.

          -  Minimum weight of 45 kg with Body mass index (BMI) between 18 and 29.5 kg/m2,
             inclusive.

          -  Understands the procedures and requirements of the study and provides written informed
             consent and authorization for protected health information disclosure

          -  Willing and able to comply with the requirements of the study protocol.

        Exclusion Criteria:

          -  Current or past history of cardiovascular, cerebrovascular, pulmonary,
             gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic,
             neurologic, dermatologic, psychiatric, or other major disease, history of cancer
             (except non-melanoma skin cancer) or history of chemotherapy use.

          -  Any surgical or medical condition or history that may potentially alter the
             absorption, metabolism, or excretion of study treatment, such as, but not limited to
             gastric bypass surgery or gastric or duodenal ulcers.

          -  History of severe allergic or anaphylactic reactions.

          -  Chronic daily medication use.

          -  History of drug abuse

          -  Excessive alcohol consumption

          -  Smoking and the use of nicotine-containing products

          -  Consumption of grapefruit or grapefruit juice, pomelo, star fruit, Seville or Moro
             (blood) orange, or their associated products

          -  Participation in another clinical trial or exposure to any investigational agent.

          -  Donation of blood or significant blood loss or plasma donation.

          -  Any condition that would interfere with the ability to provide informed consent,
             comply with study instructions, or which might confound the interpretation of the
             study results or put the patient at undue risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akebia</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2018</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vadadustat</keyword>
  <keyword>AKB-6548</keyword>
  <keyword>hypoxia-inducible factor</keyword>
  <keyword>HIF</keyword>
  <keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
  <keyword>HIF-PHI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

